We show that by distinguishing pathways known to activate these GPR43 promoter elements, it is possible to predict stimuli and conditions that may alter GPR43 expression and function, thus providing novel drug targets for the treatment of GPR43-associated diseases such as obesity, colitis, asthma and arthritis. This evidence concerns the gene FFAR2 and obesity disorder.